Recursion Pharmaceuticals (RXRX), Crispr Therapeutics (CRSP), iShares MSCI India (INDA), Faraday Future Intelligent Electric (FFIE), Bilibili (BILI), Procter & Gamble (PG), UP Fintech Holding Ltd ...

Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to ...

In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $8.50, indicating a +1.92% shift from the previous trading day.

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in ...

Recursion Pharmaceuticals (RXRX) is a clinical-stage biotechnology company utilizing artificial intelligence to expedite drug ...

The chip maker got a shout out from Amazon CEO Andy Jassy on a fourth-quarter earnings call with analysts. Trump's tariffs on Canada and Mexico are delayed. Economic turmoil is here. Big Tech is a ...

Cathie Wood says most profound application of AI is in healthcare. She particularly expects Recursion Pharma and Illumina to ...

Clear Creek Financial Management LLC lifted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 57.6% during the fourth quarter, according to its most recent 13F filing with ...

Don’t look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive ...